Status:
TERMINATED
Ambisome in Liver Transplant Patients
Lead Sponsor:
The University of Texas Health Science Center, Houston
Conditions:
Liver Transplantation
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
In this study we are trying to find out the amount of a drug called Ambisome in the liver, the blood, the bile and the fatty tissues of the body. This drug is approved for treatment of infections caus...
Detailed Description
Fungal infections continue to be a source of serious morbidity and mortality in liver transplant patients. Liposomal Amphotericin B (AmBisome ®) has been shown in animals to be concentrated in the liv...
Eligibility Criteria
Inclusion
- All adult liver transplant recipients receiving cadaveric liver transplants
Exclusion
- Patients with choledocho-jejunostomy reconstruction of the biliary tree.
- Children less than 18 years of age
- Patients with known allergy to Amphotericin B.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00161356
Start Date
September 1 2005
End Date
December 1 2007
Last Update
June 23 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Hermann Hospital
Houston, Texas, United States, 77030